Padmanabhan Eangoor
Research Subjects
Research Interests
Padmanabhan Eangoor has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
A S Indapurkar
Department of Pharmaceutical Sciences , Mercer University , 3001 Mercer University Dr, Atlanta, GA-30341, USA
1 shared publicationAbdelghani Achab
Discovery Chemistry; ; ; ; ; ; ;, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
1 shared publicationAdam Beard
Discovery Chemistry; ; ; ; ; ; ;, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
1 shared publicationAjay K. Banga
Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA
1 shared publicationAmruta Sanjay Indapurkar
Department of Pharmaceutical Sciences, 3001 Mercer University Dr, Atlanta, GA-30341, USA.
1 shared publicationAnandan Palani
External Discovery Chemistry; ; ; ; ; ; ;, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
1 shared publication
Latest Publications
- 1 December 2020
- Published by Taylor & Francis in Bioanalysis
- Vol. 12 (24) , 1757-1766
Evaluation of Homogeneous Proximity Immunoassays for Preclinical Bioanalysis
Drug discovery is moving at a rapid pace and a fast turnaround of bioanalytical data is needed to sustain this pace. This article focuses on the evaluation of time-saving homogeneous proximity immu...
- 1 December 2020
- Published by Taylor & Francis in Bioanalysis
- Vol. 12 (24) , 1757-1766
Evaluation of Homogeneous Proximity Immunoassays for Preclinical Bioanalysis
Drug discovery is moving at a rapid pace and a fast turnaround of bioanalytical data is needed to sustain this pace. This article focuses on the evaluation of time-saving homogeneous proximity immu...
- 6 August 2020
- Published by Taylor & Francis in Bioanalysis
- Vol. 12 (16) , 1105-1110
A Guided Approach to Preclinical Bioanalysis of Proteins Using Immunoassays for Pharmacokinetic and Pharmacodynamic Assessments
- 6 August 2020
- Published by Taylor & Francis in Bioanalysis
- Vol. 12 (16) , 1105-1110
A Guided Approach to Preclinical Bioanalysis of Proteins Using Immunoassays for Pharmacokinetic and Pharmacodynamic Assessments
- 23 March 2020
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 11 (4) , 582-588
Discovery and Optimization of Rationally Designed Bicyclic Inhibitors of Human Arginase to Enhance Cancer Immunotherapy
The action of arginase, a metalloenzyme responsible for the hydrolysis of arginine to urea and ornithine, is hypothesized to suppress immune-cell activity within the tumor microenvironment, and thus its inhibition may constitute a means by which to potentiate the efficacy of immunotherapeutics such as anti-PD-1 checkpoint inhibitors. Taking inspiration from reported enzyme–inhibitor cocrystal structures, we designed and synthesized novel inhibitors of human arginase possessing a fused 5,5-bicyclic ring system. The prototypical member of this class, 3, when dosed orally, successfully demonstrated serum arginase inhibition and concomitant arginine elevation in a syngeneic mouse carcinoma model, despite modest oral bioavailability. Structure-based design strategies to improve the bioavailability of this class, including scaffold modification, fluorination, and installation of active-transport recognition motifs were explored.
- 23 March 2020
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 11 (4) , 582-588
Discovery and Optimization of Rationally Designed Bicyclic Inhibitors of Human Arginase to Enhance Cancer Immunotherapy
The action of arginase, a metalloenzyme responsible for the hydrolysis of arginine to urea and ornithine, is hypothesized to suppress immune-cell activity within the tumor microenvironment, and thus its inhibition may constitute a means by which to potentiate the efficacy of immunotherapeutics such as anti-PD-1 checkpoint inhibitors. Taking inspiration from reported enzyme–inhibitor cocrystal structures, we designed and synthesized novel inhibitors of human arginase possessing a fused 5,5-bicyclic ring system. The prototypical member of this class, 3, when dosed orally, successfully demonstrated serum arginase inhibition and concomitant arginine elevation in a syngeneic mouse carcinoma model, despite modest oral bioavailability. Structure-based design strategies to improve the bioavailability of this class, including scaffold modification, fluorination, and installation of active-transport recognition motifs were explored.
- 3 July 2019
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 144 (15) , 4702-4707
Multiplexed ELISA screening assay for nine paralytic shellfish toxins in human plasma
Paralytic shellfish poisoning is a lethal syndrome that can develop in humans who consume shellfish contaminated with paralytic shellfish toxins. These toxins have a short half-life in the human body, so a rapid diagnostic assessment of the poisoning is necessary. In this paper, we have developed and validated a rapid ELISA screening assay using anti-saxitoxin antibodies to screen nine toxins: saxitoxin; decarbamoyl saxitoxin; gonyautoxin 2,3; decarbamoyl GTX 2,3; neosaxitoxin; and gonyautoxin 1,4, in human plasma with lower limits of detection of 0.02, 0.08, 0.12, 1.2, 5.0, and 25 ng mL−1, respectively. Intra-day and inter-day precision experiments showed good reproducibility with a percent coefficient of variation less than 15%. The assay was 100% accurate in determining the presence or absence of these toxins in human plasma specimens. Blank specimens were assessed as negative for toxin content indicating that the method has excellent analyte specificity. This rapid screening assay can be used to quickly diagnose exposure to paralytic shellfish toxins, though an additional confirmatory method will be necessary to identify and quantitate the specific toxin in an exposure.
- 3 July 2019
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 144 (15) , 4702-4707
Multiplexed ELISA screening assay for nine paralytic shellfish toxins in human plasma
Paralytic shellfish poisoning is a lethal syndrome that can develop in humans who consume shellfish contaminated with paralytic shellfish toxins. These toxins have a short half-life in the human body, so a rapid diagnostic assessment of the poisoning is necessary. In this paper, we have developed and validated a rapid ELISA screening assay using anti-saxitoxin antibodies to screen nine toxins: saxitoxin; decarbamoyl saxitoxin; gonyautoxin 2,3; decarbamoyl GTX 2,3; neosaxitoxin; and gonyautoxin 1,4, in human plasma with lower limits of detection of 0.02, 0.08, 0.12, 1.2, 5.0, and 25 ng mL−1, respectively. Intra-day and inter-day precision experiments showed good reproducibility with a percent coefficient of variation less than 15%. The assay was 100% accurate in determining the presence or absence of these toxins in human plasma specimens. Blank specimens were assessed as negative for toxin content indicating that the method has excellent analyte specificity. This rapid screening assay can be used to quickly diagnose exposure to paralytic shellfish toxins, though an additional confirmatory method will be necessary to identify and quantitate the specific toxin in an exposure.
- 1 December 2017
- Published by Elsevier in Journal of Controlled Release
- Vol. 268, 159-165
Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy
- 1 December 2017
- Published by Elsevier in Journal of Controlled Release
- Vol. 268, 159-165
Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy
- Open Access
- 30 August 2017
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 41 (9) , 755-759
Rapid and Sensitive ELISA Screening Assay for Several Paralytic Shellfish Toxins in Human Urine
Paralytic shellfish poisoning is caused by a group of paralytic shellfish toxins that are produced by dinoflagellates. Toxins in this group include saxitoxin, neosaxitoxin and gonyautoxins. A rapid diagnostic test to identify poisoning by these toxins can be helpful in guiding the appropriate treatment of victims. Additionally, quick receipt of diagnostic results can provide timely proof that shellfish harvesting should be stopped in a given area, thereby preventing additional exposures. We have developed and validated a rapid urinary enzyme-linked immunosorbent assay-based screening test to diagnose exposure to several major paralytic shellfish toxins. The lower limit of detection (LLOD) for multiple paralytic shellfish toxins was characterized as 0.02, 0.10, 0.10, 1.0, 1.0 and 15 ng/mL for saxitoxin, gonyautoxin 2,3, decarbamoyl gonyautoxin 2,3, decarbamoyl saxitoxin, neosaxitoxin and gonyautoxin 1,4, respectively. No interferences were identified in unspiked pooled urine or in specimens collected from unexposed individuals indicating that this method is specific for the paralytic shellfish toxins tested. The accuracy of this test was demonstrated in 10 individual urine specimens with osmolalities ranging from 217 to 1,063 mOsmol/kg and pHs ranging between 5.06 and 7.45. These specimens were spiked with toxins at their LLODs and the presence of toxins at these concentrations was accurately identified in all cases. These results indicate that this diagnostic test can be used to rapidly and accurately screen urine for paralytic shellfish toxins.
- 30 August 2017
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 41 (9) , 755-759
Open AccessRapid and Sensitive ELISA Screening Assay for Several Paralytic Shellfish Toxins in Human Urine
Paralytic shellfish poisoning is caused by a group of paralytic shellfish toxins that are produced by dinoflagellates. Toxins in this group include saxitoxin, neosaxitoxin and gonyautoxins. A rapid diagnostic test to identify poisoning by these toxins can be helpful in guiding the appropriate treatment of victims. Additionally, quick receipt of diagnostic results can provide timely proof that shellfish harvesting should be stopped in a given area, thereby preventing additional exposures. We have developed and validated a rapid urinary enzyme-linked immunosorbent assay-based screening test to diagnose exposure to several major paralytic shellfish toxins. The lower limit of detection (LLOD) for multiple paralytic shellfish toxins was characterized as 0.02, 0.10, 0.10, 1.0, 1.0 and 15 ng/mL for saxitoxin, gonyautoxin 2,3, decarbamoyl gonyautoxin 2,3, decarbamoyl saxitoxin, neosaxitoxin and gonyautoxin 1,4, respectively. No interferences were identified in unspiked pooled urine or in specimens collected from unexposed individuals indicating that this method is specific for the paralytic shellfish toxins tested. The accuracy of this test was demonstrated in 10 individual urine specimens with osmolalities ranging from 217 to 1,063 mOsmol/kg and pHs ranging between 5.06 and 7.45. These specimens were spiked with toxins at their LLODs and the presence of toxins at these concentrations was accurately identified in all cases. These results indicate that this diagnostic test can be used to rapidly and accurately screen urine for paralytic shellfish toxins.
- 1 April 2014
- Published by Elsevier in Protein Expression and Purification
- Vol. 96, 48-53
A semi-automated method for purification of milligram quantities of proteins on the QIAcube
- 1 April 2014
- Published by Elsevier in Protein Expression and Purification
- Vol. 96, 48-53
A semi-automated method for purification of milligram quantities of proteins on the QIAcube